TA
REGN icon

Thor Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Thor Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$21K Buy
+42
New +$17.3K 1.1% 12
2019
Q1 		$32K Buy
+78
New +$32.1K 0.4% 117

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Thor Advisors's REGN Position: Q1 2020 in Review

Thor Advisors opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2020: 42 shares worth $21K. The stake represents 1.1% of the portfolio and ranks #12 among its holdings. This is a return to the name: Thor Advisors previously reported a position in REGN as recently as Q1 2019.

Thor Advisors first reported a position in REGN in Q1 2019 and has held it in 2 quarters since. The position peaked at $32K in Q1 2019. 816 funds tracked by Wall St. Rank hold REGN as of Q1 2020.

  • Thor Advisors held 42 shares of Regeneron Pharmaceuticals worth $21K as of Q1 2020.
  • Regeneron Pharmaceuticals was a new Thor Advisors position in Q1 2020.
  • Regeneron Pharmaceuticals made up 1.1% of Thor Advisors's portfolio in Q1 2020, its #12 holding.
  • Thor Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2019 and has held it in 2 quarters since.
  • Thor Advisors's Regeneron Pharmaceuticals position peaked at $32K in Q1 2019.
  • 816 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2020.

Based on Thor Advisors's 13F filing for Q1 2020, filed 18 May 2020.